VopU is a novel T3SS effector protein with mono-ADP-ribosyltransferase activity and a non-canonical H-Y-Q catalytic triad
Sebastián A. Jerez, Maria J Puentes-Maldonado, Victor Cabrera, Fernando A. AmayaiD, Linda J. KenneyiD, Carlos A. SantiviagoiD, Carlos J. BlondeliD
Abstract
Vibrio parahaemolyticus utilizes its second Type III Secretion System (T3SS2) to deliver a suite of effector proteins that subvert eukaryotic host cell processes. In this study, we characterize VPA1312, renamed VopU, as a novel T3SS2 effector. We demonstrate that VopU is translocated into infected cells via the T3SS2 and independently of the VocC chaperone. From bioinformatic analyses, VopU is a member of a family of proteins distributed across diverse bacterial taxa and in some cases associated with T6SS gene clusters and plasmids. Sequence, structure-based, and functional analysis reveals that VopU harbors an ADP-ribosyltransferase domain with a non-canonical H-Y-Q catalytic triad, a motif not previously described in naturally occurring mono-ADP-ribosyltransferases. Heterologous expression of VopU within transfected cells or translocation of VopU during infection results in the ADP-ribosylation of a small protein of approximately 18 kDa protein distinct from the target of the previously described ADP-ribosyltransferase effector, VopT. While VopU is not essential for T3SS2-dependent cytotoxicity or intracellular survival of V. parahaemolyticus, heterologous expression of VopU induces host cell rounding and a transcriptional host stress response, likely linked to NAD depletion. These findings provide the initial characterization of this novel family of mono-ADP-ribosyltransferases and expand the known repertoire of bacterial effectors that mediate orthogonal post-translational modifications during host infection. IMPORTANCEVibrio parahaemolyticus is a leading cause of seafood-borne illness worldwide. To cause disease, the bacterium relies on a Type III Secretion System to deliver effector proteins into the cytosol of infected cells, subverting cellular processes. In this study, we identified a novel effector protein, VopU, which performs a post-translational modification known as ADP-ribosylation using a non-canonical catalytic triad (H-Y-Q). This is the first description of a naturally occurring mono-ART with this specific motif. We showed that VopU homologs are distributed across other bacterial species, and that VopU is active during infection of host cells. Together, our findings identify a novel family of effectors that can modify host proteins and potentially contribute to host colonization during infection.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of a family of Vibrio type III secretion system effectors that contain a conserved serine/threonine kinase domain
N. Plaza, I. M. Urrutia, … C. J. Blondel·bioRxiv·Dec 11, 2020
- Vibrio campbellii encodes a distinct set of type III secretion system effectors that mediate cytotoxicity in eukaryotic host models
Payel Paul, Shir Mass, … Julia C. van Kessel·bioRxiv·Jun 3, 2026
- Manipulation of IRE1-dependent MAPK signaling by a Vibrio agonist-antagonist effector pair
N. J. De Nisco, A. K. Casey, … K. Orth·bioRxiv·Sep 1, 2020
- The Vibrio Type III Secretion System 2 is not restricted to the Vibrionaceae and encodes differentially distributed repertoires of effector proteins
S. A. Jerez, N. Plaza, … C. J. Blondel·Microbial GenomicsPeer-reviewed·Apr 5, 2023
- Enzymatic Specificity of Conserved Rho GTPase Deamidases Promotes Invasion of Vibrio parahaemolyticus at the Expense of Infection
K. Orth, A. E. Lafrance, … K. G. Kaval·bioRxiv·Jun 13, 2022
- T3SS effector VopL inhibits the host ROS response, promoting the intracellular survival of Vibrio parahaemolyticus
M. de Souza Santos, D. Salomon, K. Orth·bioRxiv·Jan 30, 2017